Literature DB >> 20399781

Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis.

Marianne Ziol1, Jean-Charles Nault, Mounir Aout, Nathalie Barget, Maryline Tepper, Antoine Martin, Jean-Claude Trinchet, Nathalie Ganne-Carrié, Eric Vicaut, Michel Beaugrand, Gisele N'Kontchou.   

Abstract

BACKGROUND & AIMS: The expression of biliary lineage markers such as cytokeratin (K) 7 by hepatocytes is thought to reflect an altered regeneration pathway recruiting a stem cell compartment, more prone to carcinogenesis. We aimed to investigate the presence of these so-called intermediate hepatobiliary cells (IHC) in liver biopsies of patients with hepatitis C-related cirrhosis and their potential influence on the subsequent occurrence of hepatocellular carcinoma (HCC).
METHODS: From a cohort of patients with hepatitis C-related cirrhosis, prospectively screened for HCC, we retrospectively selected those with a liver biopsy performed for the initial diagnosis of cirrhosis. Presence of IHC was recorded when foci of K7-positive, intermediate-sized hepatocytes were detected.
RESULTS: A total of 150 patients were included (87 men; mean age, 57 y; range, 19-84 y; body mass index, 25 kg/m(2)). After a median follow-up period of 4.85 years, HCC was diagnosed in 36 patients (24%). Baseline liver biopsy showed intermediate hepatobiliary cell foci in 61 patients (41%). Intermediate cells co-expressed both hepatocytes markers and the progenitor cell markers Ep-CAM and K19. The presence of intermediate hepatobiliary cells was associated independently with HCC occurrence (Fine and Gray model; hazard ratio, 2.48; 95% confidence interval, 1.24-4.96; P = .01). Other predictors of HCC were diabetes and low platelet count. The HCC annual incidence rate was significantly higher in patients with IHC compared with patients without (8.14% vs 3.12%, Gray's test, P = .003).
CONCLUSIONS: The aberrant expression of biliary K by hepatocytes in patients with hepatitis C virus-related cirrhosis is related independently to HCC occurrence. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399781     DOI: 10.1053/j.gastro.2010.04.012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.

Authors:  Danielle K DePeralta; Lan Wei; Sarani Ghoshal; Benjamin Schmidt; Gregory Y Lauwers; Michael Lanuti; Raymond T Chung; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Cancer       Date:  2016-02-23       Impact factor: 6.860

2.  Neighbourhood deaths cause a switch in cancer subtype.

Authors:  Eli Pikarsky
Journal:  Nature       Date:  2018-10       Impact factor: 49.962

3.  Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma.

Authors:  Xiong Cai; Jian Zhai; David E Kaplan; Yijun Zhang; Lining Zhou; Xutao Chen; Guangyang Qian; Qiudong Zhao; Yonghai Li; Lu Gao; Wenming Cong; Minghua Zhu; Zhenlin Yan; Lehua Shi; Dong Wu; Lixin Wei; Feng Shen; Mengchao Wu
Journal:  Hepatology       Date:  2012-06-25       Impact factor: 17.425

Review 4.  Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers.

Authors:  Regina Cheuk-Lam Lo; Irene Oi-Lin Ng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

5.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

6.  Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.

Authors:  Hidenao Noritake; Yoshimasa Kobayashi; Yukimasa Ooba; Erika Matsunaga; Kazuyoshi Ohta; Shin Shimoyama; Satoru Yamazaki; Takeshi Chida; Kazuhito Kawata; Takanori Sakaguchi; Takafumi Suda
Journal:  J Interferon Cytokine Res       Date:  2015-08-26       Impact factor: 2.607

Review 7.  Cancer stem cells in the development of liver cancer.

Authors:  Taro Yamashita; Xin Wei Wang
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

8.  Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models.

Authors:  Keane K Y Lai; Sufen Shang; Neha Lohia; Garrett C Booth; Derek J Masse; Nelson Fausto; Jean S Campbell; Laura Beretta
Journal:  PLoS Genet       Date:  2011-06-23       Impact factor: 5.917

9.  Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review.

Authors:  Chenhui Ma; Na Wang; Huanhuan Ma; Kewei Song; Rong Yu; Hao Chen
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

10.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.